Nisha Jain

713 total citations
27 papers, 474 citations indexed

About

Nisha Jain is a scholar working on Hematology, Genetics and Immunology. According to data from OpenAlex, Nisha Jain has authored 27 papers receiving a total of 474 indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Hematology, 6 papers in Genetics and 3 papers in Immunology. Recurrent topics in Nisha Jain's work include Hemophilia Treatment and Research (17 papers), Platelet Disorders and Treatments (11 papers) and Blood Coagulation and Thrombosis Mechanisms (7 papers). Nisha Jain is often cited by papers focused on Hemophilia Treatment and Research (17 papers), Platelet Disorders and Treatments (11 papers) and Blood Coagulation and Thrombosis Mechanisms (7 papers). Nisha Jain collaborates with scholars based in United States, Canada and Sweden. Nisha Jain's co-authors include L. Ross Pierce, Elisa Tsao, Jennifer Dumont, Bent Winding, Roshni Kulkarni, Natalya M. Ananyeva, Amy D. Shapiro, Johnny Mahlangu, Manuel Carção and Evgueni L. Saenko and has published in prestigious journals such as Blood, Science Translational Medicine and Journal of Thrombosis and Haemostasis.

In The Last Decade

Nisha Jain

26 papers receiving 452 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Nisha Jain United States	10	288	99	62	46	44	27	474
M. S. Kennedy United States	7	228 0.8×	77 0.8×	28 0.5×	33 0.7×	68 1.5×	9	383
Pragya Shrestha United States	13	45 0.2×	72 0.7×	28 0.5×	18 0.4×	12 0.3×	38	435
Hoi Soo Yoon South Korea	13	148 0.5×	63 0.6×	18 0.3×	9 0.2×	26 0.6×	35	410
Fatih Azık Türkiye	10	131 0.5×	33 0.3×	60 1.0×	15 0.3×	49 1.1×	51	271
Gilwan Kim United States	13	74 0.3×	118 1.2×	27 0.4×	17 0.4×	14 0.3×	28	447
Carolina Pérez-García Spain	13	72 0.3×	81 0.8×	30 0.5×	7 0.2×	10 0.2×	38	371
Stefania Manganelli Italy	12	59 0.2×	69 0.7×	18 0.3×	17 0.4×	5 0.1×	19	485
Erdal Diri United States	10	99 0.3×	33 0.3×	9 0.1×	25 0.5×	17 0.4×	13	551
Donata Marra France	6	32 0.1×	51 0.5×	49 0.8×	23 0.5×	8 0.2×	10	375
Khaldoon Alawneh Jordan	12	60 0.2×	48 0.5×	31 0.5×	7 0.2×	7 0.2×	29	305

Countries citing papers authored by Nisha Jain

Since Specialization

Citations

This map shows the geographic impact of Nisha Jain's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nisha Jain with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nisha Jain more than expected).

Fields of papers citing papers by Nisha Jain

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nisha Jain. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nisha Jain. The network helps show where Nisha Jain may publish in the future.

Co-authorship network of co-authors of Nisha Jain

This figure shows the co-authorship network connecting the top 25 collaborators of Nisha Jain. A scholar is included among the top collaborators of Nisha Jain based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nisha Jain. Nisha Jain is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Malec, Lynn, An Van Damme, Anthony K.C. Chan, et al.. (2023). Recombinant factor VIII Fc fusion protein for first-time immune tolerance induction: final results of the verITI-8 study. Blood. 141(16). 1982–1989. 9 indexed citations

Shapiro, Amy D., Roshni Kulkarni, Margaret V. Ragni, et al.. (2023). Post hoc longitudinal assessment of the efficacy and safety of recombinant factor IX Fc fusion protein in hemophilia B. Blood Advances. 7(13). 3049–3057. 4 indexed citations

Palanca, Ben Julian A., Charles R. Conway, Thomas A. Zeffiro, et al.. (2023). Persistent Brain Connectivity Changes in Healthy Volunteers Following Nitrous Oxide Inhalation. Biological Psychiatry Global Open Science. 3(4). 698–704. 2 indexed citations

Jain, Nisha, et al.. (2022). Recent advances in therapeutic options for rare hemostatic disorders: selected poster extracts of recent research in hemophilia A, congenital hemophilia with inhibitors, von Willebrand disease, and thrombotic thrombocytopenic purpura presented at the 29th congress of the International Society on Thrombosis and Haemostasis (ISTH 2021, Jul 17–21; virtual congress). Expert Review of Hematology. 15(sup1). 1–18. 1 indexed citations

Turecek, Peter L., Savita Rangarajan, Michael Laffan, et al.. (2021). Recombinant ADAMTS13 reduces abnormally up-regulated von Willebrand factor in plasma from patients with severe COVID-19. Thrombosis Research. 201. 100–112. 34 indexed citations

Nägele, Peter, Ben Julian A. Palanca, Britt M. Gott, et al.. (2021). A phase 2 trial of inhaled nitrous oxide for treatment-resistant major depression. Science Translational Medicine. 13(597). 61 indexed citations

Jain, Nisha, et al.. (2021). Recombinant ADAMTS13 for Patients with Severe Congenital Thrombotic Thrombocytopenic Purpura: Design of a Phase 3b Open-Label Continuation Study of Prophylactic and on-Demand Treatment. Blood. 138(Supplement 1). 4252–4252. 4 indexed citations

Patwari, Parth, et al.. (2021). Recombinant ADAMTS13 for Patients with Sickle Cell Disease: Design of a Phase 1 Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study. Blood. 138(Supplement 1). 3118–3118. 2 indexed citations

Shrestha, Anshu, Jun Su, Nanxin Li, et al.. (2020). Physical activity and bleeding outcomes among people with severe hemophilia on extended half‐life or conventional recombinant factors. Research and Practice in Thrombosis and Haemostasis. 5(1). 94–103. 7 indexed citations

10.

Shapiro, Amy D., Michael Wang, Miguel A. Escobar, et al.. (2020). Real‐world data demonstrate improved bleed control and extended dosing intervals for patients with haemophilia B after switching to recombinant factor IX Fc fusion protein (rFIXFc) for up to 5 years. Haemophilia. 26(6). 975–983. 10 indexed citations

11.

Botteman, Marc, et al.. (2019). PRO69 PATIENT AND CAREGIVER PREFERENCES FOR CHARACTERISTICS OF TREATMENT IN HEMOPHILIA A: LITERATURE REVIEW AND QUALITATIVE RESEARCH. Value in Health. 22. S348–S348. 1 indexed citations

12.

Su, Jun, et al.. (2019). Cold Agglutinin Disease Transfusion Practices in the United States: An Electronic Medical Record-Based Analysis. Blood. 134(Supplement_1). 3690–3690.

13.

Aledort, Louis M., et al.. (2018). Changing the Paradigm in Hemophilia Care: Extended Half-Life Products (rFVIIIFc and rFIXFc). Blood. 132(Supplement 1). 3514–3514. 2 indexed citations

14.

Oldenburg, Johannes, Roshni Kulkarni, Alok Srivastava, et al.. (2017). Improved joint health in subjects with severe haemophilia A treated prophylactically with recombinant factor VIII Fc fusion protein. Haemophilia. 24(1). 77–84. 38 indexed citations

15.

Kulkarni, Rajendra, Ri Liesner, Hideji Hanabusa, et al.. (2016). Post hoc analysis to evaluate the effect of recombinant factor IX Fc fusion protein (rFIXFc) prophylaxis in adults and adolescents with target joints and hemophilia B. Queen Mary Research Online (Queen Mary University of London). 3 indexed citations

16.

Sridhar, GR, Mikhail V. Ovanesov, Richard A. Forshee, et al.. (2015). Clotting factor product administration and same‐day occurrence of thrombotic events, as recorded in a large healthcare database during 2008–2013. Journal of Thrombosis and Haemostasis. 13(12). 2168–2179. 20 indexed citations

17.

Shibeko, A. M., et al.. (2014). Predicting dosing advantages of factor VIIa variants with altered tissue factor‐dependent and lipid‐dependent activities. Journal of Thrombosis and Haemostasis. 12(8). 1302–1312. 8 indexed citations

18.

Jain, Nisha, et al.. (2011). Maternal mortality in an urban tertiary care hospital of north India. The Journal of Obstetrics and Gynecology of India. 61(3). 280–285. 38 indexed citations

19.

Ananyeva, Natalya M., Timothy Lee, Nisha Jain, Midori Shima, & Evgueni L. Saenko. (2009). Inhibitors in Hemophilia A: Advances in Elucidation of Inhibitory Mechanisms and in Inhibitor Management with Bypassing Agents. Seminars in Thrombosis and Hemostasis. 35(8). 735–751. 18 indexed citations

20.

Pierce, L. Ross & Nisha Jain. (2003). Risks associated with the use of intravenous immunoglobulin 1 1This review article reflects the opinions of the authors and not necessarily those of the U.S. Food and Drug Administration.. Transfusion Medicine Reviews. 17(4). 241–251. 152 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact